- 25 mg - Cyclosporine USP;
- 50 mg - Cyclosporine USP;
- 100 mg - Cyclosporine USP;
Without a Prescription
Cyclosporine is prescribed for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.
While rebound rarely occurs, most patients will experience relapse with Cyclosporine as with other therapies upon cessation of treatment.
Cyclosporine is prescribed for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone.
Kidney, Liver and Heart Transplantation
Cyclosporine is prescribed for the prophylaxis of organ rejection in kidney, liver and heart allogeneic transplants. Cyclosporine has been used in combination with azathioprine and corticosteroids.
Cyclosporine has increased bioavailability in comparison to conventional cyclosporine. Cyclosporine and conventional cyclosporine are
not bioequivalent and cannot be used interchangeably without physician supervision.
The daily dose of Cyclosporine should always be given in two divided doses (BID). Cyclosporine is recommended that Cyclosporine be
administered on a consistent schedule with regard to time of day and relation to meals. Grapefruit and grapefruit juice affect
metabolism, increasing blood concentration of cyclosporine, thus should be avoided.
Rheumatoid Arthritis: The initial dose of Cyclosporine is 2.5 mg/kg/day, taken twice daily as a divided (BID) oral dose.
Salicylates, nonsteroidal anti-inflammatory agents, and oral corticosteroids may be continued. Onset of action generally occurs
between 4 and 8 weeks. If insufficient clinical benefit is seen and tolerability is good (including serum creatinine less than
30% above baseline), the dose may be increased by 0.5-0.75 mg/kg/day after 8 weeks and again after 12 weeks to a maximum of 4 mg/kg/day. If no benefit is seen by 16 weeks of therapy, Cyclosporine therapy should be discontinued.
Psoriasis: The initial dose of Cyclosporine should be 2.5 mg/kg/day. Cyclosporine should be taken twice daily, as a divided (1.25 mg/kg BID) oral
dose. Patients should be kept at that dose for at least 4 weeks, barring adverse events. If significant clinical improvement has not
occurred in patients by that time, the patient`s dosage should be increased at 2-week intervals. Based on patient response, dose increases of approximately 0.5 mg/kg/day should be made to a maximum of 4.0 mg/kg/day.
Dose decreases by 25%-50% should be made at any time to control adverse events, e.g., hypertension, elevations in serum creatinine (>/=25% above
the patient`s pretreatment level), or clinically significant laboratory abnormalities. If dose reduction is not effective in controlling abnormalities, or if the adverse event or abnormality is severe, Cyclosporine should be discontinued.
Psoriasis patients who are treated with Cyclosporine should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension or malignancies should not receive Cyclosporine .
Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension or malignancies should not receive Cyclosporine .
Cyclosporine is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation.
Strip of 5 capsules.